Company intelligence / Profile preview

Piramed

Slough, England, United Kingdompyramidmodel.org ↗

Ownership: Private
Development stage: Other

Overview

Piramed developed small molecule inhibitors targeting the PI3K pathway for oncology and inflammatory diseases. Its lead compound in oncology entered Phase I clinical trials in collaboration with Genentech. The inflammatory disease program was preclinical at the time of Roche’s acquisition. GDC‑0941, a PI3K inhibitor discovered by Piramed, advanced to clinical development under Genentech/Roche. No commercialized products prior to acquisition.

Therapeutic areas: ImmunologyOncology
Modalities: Small moleculeSignal transduction inhibitor
Industry: Biotech

Partnerships

Genentech — R&D and licensing partnership for PI3K inhibitors/GDC–0941/pictilisib; later part of Roche group after its full acquisition of Genentech.

Beyond the preview

Go deeper on Piramed.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Piramed.

Explore the full profile